Amgen's Maritide Shows Promising Phase 2 Weight Loss Data
Amgen presents phase 2 results for maritide, demonstrating significant weight loss with a convenient monthly injection schedule that could differentiate it in the competitive obesity market.
Amgen unveiled promising phase 2 data for maritide (formerly MariTide/AMG 133), its investigational GLP-1/GIP receptor modulator, at a medical conference this week. The results demonstrated meaningful weight loss with a monthly injection schedule, potentially offering a significant convenience advantage over current weekly options while achieving competitive efficacy.
What We Know
The phase 2 trial enrolled approximately 590 adults with obesity, randomizing participants to various maritide doses or placebo for 52 weeks [amgen-phase2-2025]. The highest dose cohort achieved mean weight loss of approximately 20% from baseline, placing maritide in the same efficacy range as leading competitors.
What distinguishes maritide is its pharmacokinetic profile enabling monthly administration. While semaglutide and tirzepatide require weekly injections, maritide’s extended half-life allows for dosing every four weeks, representing a potential practical advantage for patients who find frequent injections burdensome [monthly-dosing-review].
The safety profile was generally consistent with the GLP-1 class, with gastrointestinal adverse events being most common. Nausea occurred in approximately 35% of participants at the highest dose, though rates decreased over time. Discontinuation rates due to adverse events were comparable to other medications in the class.
Unique Mechanism
Maritide differs mechanistically from some competitors. It functions as a GLP-1 receptor agonist but as a GIP receptor antagonist, rather than the dual agonism seen with tirzepatide. This distinct pharmacology may produce different effects on metabolism and could influence the side effect profile [endocrine-society-2025].
The rationale for GIP antagonism stems from research suggesting that blocking GIP signaling in certain tissues may enhance weight loss effects. However, this remains an area of active investigation, and head-to-head comparisons will ultimately determine whether the mechanistic difference translates to clinical advantages.
Amgen has also emphasized the potential for weight loss maintenance. Extended dosing intervals might support better long-term adherence, a critical factor given that obesity is a chronic condition requiring sustained treatment. Early data suggest weight stability when patients continue monthly dosing.
What It Means
The phase 2 results position Amgen as a serious entrant in the competitive obesity market, challenging the Novo Nordisk and Eli Lilly duopoly. While Amgen enters later than competitors, the differentiated profile could carve out market share, particularly among patients seeking less frequent injections.
For patients and providers, additional options in the obesity medication space are welcome. Individual responses to different medications vary, and having multiple effective options allows for personalized treatment selection. Monthly dosing could be particularly valuable for patients with injection anxiety or those with challenging schedules.
The competitive implications extend to pricing and access. A new entrant with a differentiated product could pressure pricing or expand insurance coverage as payers gain negotiating leverage. Amgen’s experience with biologic manufacturing and established relationships with payers could facilitate market access.
However, the path from phase 2 to approval remains substantial. Phase 3 trials must confirm efficacy and safety in larger populations, and manufacturing at commercial scale must be established. Amgen has indicated plans to begin phase 3 enrollment in late 2025, with potential approval in 2028 if trials succeed.
What’s Next
Amgen’s phase 3 program for maritide is expected to include multiple trials examining the medication in various populations, including those with type 2 diabetes and potentially cardiovascular outcomes.
Key questions to be addressed in phase 3 include:
Comparative efficacy: How does maritide compare directly to semaglutide or tirzepatide in randomized head-to-head trials? While cross-trial comparisons suggest competitive efficacy, definitive data require direct comparison.
Long-term maintenance: Does the monthly dosing schedule actually improve long-term adherence and weight maintenance compared to weekly options?
Safety in broader populations: Larger trials will provide more statistical power to detect rare adverse events and establish safety across diverse patient groups.
Cardiovascular outcomes: Will Amgen pursue a cardiovascular outcomes trial, which could strengthen the medication’s value proposition for payers and providers?
The obesity pharmaceutical market continues to expand rapidly, and Amgen’s entry adds another dimension to an increasingly competitive landscape. Patients ultimately benefit from innovation and competition that expands treatment options.
This information is provided for educational purposes only and does not constitute medical advice. Patients considering any medication should consult with qualified healthcare providers.
Sources & Citations
- 1
- 2
- 3
Disclaimer: This article is for educational purposes only and does not constitute medical advice. The information presented is based on current research but should not be used for diagnosis, treatment, or prevention of any disease. Always consult a qualified healthcare provider before making health decisions.